Medicaid Drug Decisions Transparency Act
A BILL
To amend title XI of the Social Security Act to expand the scope of transparency reporting requirements related to the ownership or investment interests of health care providers and others, and to increase the penalties associated with violating such requirements.
Sec. 2 Ownership or investment interest transparency for health care providers and others
“(vi) A pharmacist (as defined in section 804(a)(2) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 384(a)(2)).
“(vii) An individual or entity with decision-making authority over the formulary or preferred drug list of a State plan (or a waiver of a plan) under title XIX, including an individual or entity that participates in the establishment of such a drug formulary or preferred drug list or in the drug utilization review process for such a plan or waiver, such as a member of a State drug use review board described in section 1927.”
Sec. 3 State drug use review board membership transparency
“(i) In general—The membership”
“(ii) Requirement—The membership”
“(iii) Publication of membership—Each State shall publish a list of the DUR Board members on an Internet web site in a format that is clear and understandable and regularly shall update the list with any changes to such membership.”